Compare GSK plc (GSK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Travere Therapeutics Inc. Common Stock — how do they compare? GSK plc trades at $48.93 (market cap $96.45B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: GSK plc is far larger — about 19.2× Travere Therapeutics Inc. Common Stock's market cap, and GSK plc pays a 3.79% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GSK | TVTX | |
|---|---|---|
Market Cap | $96.45B | $5.02B |
Volume | 7,087,457 | 2,060,842 |
Sector | Health | Health |
52-Week High | $61.18 | $67.52 |
52-Week Low | $43.24 | $26.79 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $116.51B | $5.15B |
Dividend Yield | 3.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.27, down 1.39% today, with a bearish technical signal from moving averages. The company shows strong profitability with a 72.73% gross margin and 14.52% net margin, supported by recent earnings beats. Analysts are mixed with 31% buy ratings, while recent news highlights strategic oncology investments and a $750M deal for a cancer therapy.
GSK's outlook is balanced by solid fundamentals against near-term headwinds. Investment appeal lies in its high margins and pipeline growth, but risks include patent expirations and competitive pressures. The stock offers value with a P/E of 15.38, though technical weakness suggests cautious entry points.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
